Hong Kong Media Stock News

MicroPort Scientific Corporation recently issued consolidated earnings guidance indicating that for the year ended 31 December 2025 it expects a turnaround to profitability, with net profit of at least US$20 million versus an audited net loss of about US$268 million in 2024. This projected swing from a very large loss to a positive bottom line highlights a major shift in the company’s operational and financial trajectory. We will now examine how MicroPort Scientific’s anticipated return to...

We wouldn't blame Acme International Holdings Limited ( HKG:1870 ) shareholders if they were a little worried about the...

It might be of some concern to shareholders to see the MGM China Holdings Limited ( HKG:2282 ) share price down 17% in...

Key Insights Minsheng Education Group's significant insider ownership suggests inherent interests in company's...

Those holding Modern Chinese Medicine Group Co., Ltd. ( HKG:1643 ) shares would be relieved that the share price has...

Despite an already strong run, Perfect Optronics Limited ( HKG:8311 ) shares have been powering on, with a gain of 48...

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

Key Insights The projected fair value for Ferretti is HK$62.04 based on 2 Stage Free Cash Flow to Equity Ferretti is...

Whilst it may not be a huge deal, we thought it was good to see that the Texwinca Holdings Limited ( HKG:321...

With a price-to-earnings (or "P/E") ratio of 19x Galaxy Entertainment Group Limited ( HKG:27 ) may be sending very...

Genscript Biotech (SEHK:1548) is back in focus after its associate Legend Biotech reported approximately US$555 million in Q4 2025 net trade sales of multiple myeloma cell therapy CARVYKTI®, underscoring meaningful commercial traction. See our latest analysis for Genscript Biotech. Legend Biotech’s CARVYKTI® sales update has arrived after a mixed year for Genscript Biotech, with the share price at HK$13.3, a year to date share price return of 3.99%, a 1 year total shareholder return of 26.19%...

Production update and why it matters for CGN Mining CGN Mining (SEHK:1164) has released unaudited natural uranium production figures, reporting 702.5 tU for the fourth quarter of 2025 and 2,699.0 tU for the full year. This provides investors with fresh insight into recent operating performance. See our latest analysis for CGN Mining. The production update lands after a strong run in the shares. The latest HK$4.3 price comes alongside a 32.72% year to date share price return and a very large 5...

As the Asian markets navigate a landscape marked by mixed economic signals, investors are keenly observing opportunities that may arise from current market fluctuations. In this environment, identifying stocks trading at an estimated discount requires a focus on companies with strong fundamentals and resilience in the face of global uncertainties.

Record profit outlook puts recent share gains in focus COSCO SHIPPING Energy Transportation (SEHK:1138) is in the spotlight after projecting record profit for 2025 and signaling strong year-on-year growth for early 2026, supported by resilient oil transport demand and constrained shipping capacity. See our latest analysis for COSCO SHIPPING Energy Transportation. Investors have responded quickly to COSCO SHIPPING Energy Transportation’s outlook, with a 30 day share price return of 33.68% and...

Why Sany Heavy Equipment International Holdings (SEHK:631) is Back on Investor Radar Sany Heavy Equipment International Holdings (SEHK:631) has disclosed plans to subscribe for financial products from CICC Group, highlighting its capital allocation choices for investors watching how the company manages liquidity. See our latest analysis for Sany Heavy Equipment International Holdings. The intent to place funds into CICC Group products comes at a time when Sany Heavy Equipment International...

Earlier in January 2026, AbbVie and RemeGen announced an exclusive licensing agreement for RC148, a PD-1/VEGF bispecific antibody for advanced solid tumors, giving AbbVie rights outside Greater China in exchange for an upfront US$650 million payment plus very large potential milestone payments and tiered double-digit royalties. The deal not only validates RemeGen’s oncology platform but also links RC148 to AbbVie’s antibody-drug conjugate pipeline, broadening future combination therapy...

If you are wondering whether Lenovo Group's current share price lines up with its underlying value, this breakdown is designed to give you a clear, numbers first view. Lenovo's shares last closed at HK$8.84, with returns of 0.5% decline over 7 days, 5.2% decline over 30 days, 7.4% decline year to date and 3.0% decline over the past year, set against longer term returns of 58.5% over 3 years and 20.1% over 5 years. Those mixed returns have arrived as Lenovo continues to attract attention in...

Leadership change and why it matters for China Unicom (Hong Kong) China Unicom (Hong Kong) (SEHK:762) has appointed Dong Xin as both Chairman and Chief Executive Officer, a dual role that often prompts investors to reassess how leadership, governance and execution might align. See our latest analysis for China Unicom (Hong Kong). At a share price of HK$7.77, China Unicom (Hong Kong) has a 1-day share price return of 1.97%, while the 90-day share price return of 17.25% decline sits alongside a...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Generally speaking long term investing is the way to go. But unfortunately, some companies simply don't succeed. To...

With a price-to-earnings (or "P/E") ratio of 17.6x Shangri-La Asia Limited ( HKG:69 ) may be sending bearish signals at...

Why XtalPi Holdings Is On Investors’ Radar Today XtalPi Holdings (SEHK:2228) is drawing fresh attention as its AI powered drug discovery services support robust revenue growth and key healthcare AI partnerships, while some investors remain cautious about margins and cash flow. See our latest analysis for XtalPi Holdings. That stronger interest is showing up in the numbers, with a 1 month share price return of 41.89% at a latest share price of HK$13.48 and a 1 year total shareholder return of...

Dispatch Bio and CARsgen Therapeutics Holdings announced a clinical collaboration to run a Phase 1 trial in China evaluating DISP-11, combining Dispatch’s Flare platform and DV-10 virus with CARsgen’s approved BCMA-targeting CAR T therapy zevorcabtagene autoleucel in patients with epithelial solid tumors. This pairing of a tumor-specific virus that “paints” a synthetic antigen with an existing CAR T-cell therapy aims to open an immunotherapy path for solid tumors, where treatment options...